# Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

> **NCT04060459** · PHASE2 · UNKNOWN · sponsor: **Third Military Medical University** · enrollment: 50 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Paclitaxel-binding albumin

## Key facts

- **NCT ID:** NCT04060459
- **Lead sponsor:** Third Military Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2020-10
- **Final completion:** 2022-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04060459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04060459, "Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04060459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*